{"id":402971,"date":"2020-12-18T12:24:14","date_gmt":"2020-12-18T17:24:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=402971"},"modified":"2020-12-18T12:24:14","modified_gmt":"2020-12-18T17:24:14","slug":"mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\/","title":{"rendered":"Mylan Wins Summary Judgment in EpiPen\u00ae Litigation Brought by Sanofi"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n PITTSBURGH<\/span>, Dec. 18, 2020<\/span> \/PRNewswire\/ —\u00a0Viatris Inc.\u00a0(NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas<\/span> entered summary judgment in Mylan’s favor in the lawsuit brought against it by Sanofi related to its EpiPen\u00ae products.<\/p>\n

Viatris is extremely pleased with this significant action by the Court as it rejects Sanofi’s baseless attempts to argue that Mylan used anticompetitive practices to market EpiPen and goes a long way in supporting the Company’s commitment to vigorously defend itself against unfounded claims. <\/p>\n

For the past three years, Sanofi, one of the world’s largest pharmaceutical companies, has unjustly pursued money damages and attempted to blame Mylan for Sanofi’s own failures in marketing Auvi-Q. The Court’s favorable judgment should put an end to this attempt by Sanofi to advance a false narrative against Mylan and to use the antitrust laws to punish, rather than promote, competition. More than five years ago, Sanofi completely recalled Auvi-Q from the market and decided to return the product to the inventor after the product was found to potentially have inaccurate dosage delivery.<\/p>\n

\n About EpiPen
<\/b>EpiPen is used to treat life-threatening allergic reactions. Mylan has worked to allow access to Epinephrine in schools and public entities, so it can be readily available for any child who needs it. Mylan has given away more than 1 million EpiPen products to schools across America. These free pens have been used thousands of times, potentially saving lives. <\/p>\n

\n About\u00a0Viatris<\/b>\u00a0
Viatris\u00a0Inc. (NASDAQ: VTRS) is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We\u00a0provide\u00a0access to medicines, advance sustainable operations, develop innovative\u00a0solutions\u00a0and\u00a0leverage\u00a0our collective\u00a0expertise\u00a0to connect more people to more products and services through our one-of-a-kind Global Healthcare\u00a0GatewayTM<\/sup>.\u00a0Formed in November 2020<\/span> through the combination of Mylan and Pfizer’s Upjohn business,\u00a0Viatris\u00a0brings together scientific, manufacturing and distribution\u00a0expertise\u00a0with proven regulatory,\u00a0medical\u00a0and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories.\u00a0Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products.\u00a0With a global workforce of\u00a0approximately 45,000,\u00a0Viatris\u00a0is headquartered in the U.S.,\u00a0with global centers in Pittsburgh<\/span>, Shanghai<\/span> and Hyderabad<\/span>, India.\u00a0Learn more at viatris.com<\/a>\u00a0and investor.viatris.com<\/a>, and connect with us on Twitter at\u00a0@ViatrisInc<\/a><\/u>,\u00a0LinkedIn<\/a><\/u>\u00a0and\u00a0YouTube<\/a><\/u>.\u00a0<\/p>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi-301196143.html<\/a><\/p>\n

SOURCE Viatris Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire PITTSBURGH, Dec. 18, 2020 \/PRNewswire\/ —\u00a0Viatris Inc.\u00a0(NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas entered summary judgment in Mylan’s favor in the lawsuit brought against it by Sanofi related to its EpiPen\u00ae products. Viatris is extremely pleased with this significant action by the Court as it rejects Sanofi’s baseless attempts to argue that Mylan used anticompetitive practices to market EpiPen and goes a long way in supporting the Company’s commitment to vigorously defend itself against unfounded claims. For the past three years, Sanofi, one of the world’s largest pharmaceutical companies, has unjustly pursued money damages and attempted to blame Mylan for Sanofi’s own failures in marketing Auvi-Q. The Court’s favorable judgment should … <\/p>\n

Continue reading “Mylan Wins Summary Judgment in EpiPen\u00ae Litigation Brought by Sanofi”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-402971","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMylan Wins Summary Judgment in EpiPen\u00ae Litigation Brought by Sanofi - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mylan Wins Summary Judgment in EpiPen\u00ae Litigation Brought by Sanofi - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire PITTSBURGH, Dec. 18, 2020 \/PRNewswire\/ —\u00a0Viatris Inc.\u00a0(NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas entered summary judgment in Mylan’s favor in the lawsuit brought against it by Sanofi related to its EpiPen\u00ae products. Viatris is extremely pleased with this significant action by the Court as it rejects Sanofi’s baseless attempts to argue that Mylan used anticompetitive practices to market EpiPen and goes a long way in supporting the Company’s commitment to vigorously defend itself against unfounded claims. For the past three years, Sanofi, one of the world’s largest pharmaceutical companies, has unjustly pursued money damages and attempted to blame Mylan for Sanofi’s own failures in marketing Auvi-Q. The Court’s favorable judgment should … Continue reading "Mylan Wins Summary Judgment in EpiPen\u00ae Litigation Brought by Sanofi"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-18T17:24:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE29554&sd=2020-12-18\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mylan Wins Summary Judgment in EpiPen\u00ae Litigation Brought by Sanofi\",\"datePublished\":\"2020-12-18T17:24:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\\\/\"},\"wordCount\":440,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NE29554&sd=2020-12-18\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\\\/\",\"name\":\"Mylan Wins Summary Judgment in EpiPen\u00ae Litigation Brought by Sanofi - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NE29554&sd=2020-12-18\",\"datePublished\":\"2020-12-18T17:24:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NE29554&sd=2020-12-18\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NE29554&sd=2020-12-18\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mylan Wins Summary Judgment in EpiPen\u00ae Litigation Brought by Sanofi\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mylan Wins Summary Judgment in EpiPen\u00ae Litigation Brought by Sanofi - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\/","og_locale":"en_US","og_type":"article","og_title":"Mylan Wins Summary Judgment in EpiPen\u00ae Litigation Brought by Sanofi - Market Newsdesk","og_description":"PR Newswire PITTSBURGH, Dec. 18, 2020 \/PRNewswire\/ —\u00a0Viatris Inc.\u00a0(NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas entered summary judgment in Mylan’s favor in the lawsuit brought against it by Sanofi related to its EpiPen\u00ae products. Viatris is extremely pleased with this significant action by the Court as it rejects Sanofi’s baseless attempts to argue that Mylan used anticompetitive practices to market EpiPen and goes a long way in supporting the Company’s commitment to vigorously defend itself against unfounded claims. For the past three years, Sanofi, one of the world’s largest pharmaceutical companies, has unjustly pursued money damages and attempted to blame Mylan for Sanofi’s own failures in marketing Auvi-Q. The Court’s favorable judgment should … Continue reading \"Mylan Wins Summary Judgment in EpiPen\u00ae Litigation Brought by Sanofi\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-18T17:24:14+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE29554&sd=2020-12-18","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mylan Wins Summary Judgment in EpiPen\u00ae Litigation Brought by Sanofi","datePublished":"2020-12-18T17:24:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\/"},"wordCount":440,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE29554&sd=2020-12-18","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\/","name":"Mylan Wins Summary Judgment in EpiPen\u00ae Litigation Brought by Sanofi - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE29554&sd=2020-12-18","datePublished":"2020-12-18T17:24:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE29554&sd=2020-12-18","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE29554&sd=2020-12-18"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mylan Wins Summary Judgment in EpiPen\u00ae Litigation Brought by Sanofi"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/402971","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=402971"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/402971\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=402971"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=402971"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=402971"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}